Fig. 3From: Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastomaSurvival analyses depending on treatment in histological subgroups. a-d Kaplan-Meier survival curves for patients treated with nimotuzumab (nimo) or placebo (cont) in dichotomized histological subgroups (median split, above median: high, below and equal to median low) for necrosis (a), HIF-1α in perinecrotic regions (b), P-PRAS40 (c) and P-RPS6 (d). P values were calculated using the Wilcoxon testBack to article page